INFLUENCE OF SHORT-TERM VERSUS LONG-TERM DUAL ANTIPLATELET THERAPY ON BLEEDING AND ISCHEMIC OUTCOMES IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION WITH DRUG-ELUTING STENTS

Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) necessitates dual antiplatelet therapy (DAPT) to reduce thrombotic complications. However, the optimal duration of DAPT remains a topic of debate. This paper examines the influence of short-term versus long-term DAPT on bleeding and ischemic outcomes in patients undergoing PCI with DES. The literature suggests that short-term DAPT (3–6 months) may reduce major bleeding events while maintaining similar ischemic protection compared to long-term therapy (12 months or more). A systematic review of recent studies, particularly from 2023, highlights the clinical implications of DAPT duration choices. This paper includes comparative data, tables, and graphs to illustrate the risk-benefit trade-offs of each approach.